TY - JOUR
T1 - Atopic dermatitis (eczema) guidelines
T2 - 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations
AU - AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel
AU - Patient Groups: Global Parents for Eczema Research
AU - National Eczema Association
AU - Evidence in Allergy Group
AU - The AAAAI/ACAAI Joint Task Force on Practice Parameters
AU - Chu, Derek K.
AU - Schneider, Lynda
AU - Asiniwasis, Rachel Netahe
AU - Boguniewicz, Mark
AU - De Benedetto, Anna
AU - Ellison, Kathy
AU - Frazier, Winfred T.
AU - Greenhawt, Matthew
AU - Huynh, Joey
AU - Kim, Elaine
AU - LeBovidge, Jennifer
AU - Lind, Mary Laura
AU - Lio, Peter
AU - Martin, Stephen A.
AU - O'Brien, Monica
AU - Ong, Peck Y.
AU - Silverberg, Jonathan I.
AU - Spergel, Jonathan M.
AU - Wang, Julie
AU - Wheeler, Kathryn E.
AU - Guyatt, Gordon H.
AU - Capozza, Korey
AU - Begolka, Wendy Smith
AU - Chu, Alexandro W.L.
AU - Zhao, Irene X.
AU - Chen, Lina
AU - Oykhman, Paul
AU - Bakaa, Layla
AU - Golden, David
AU - Shaker, Marcus
AU - Bernstein, Jonathan A.
AU - Horner, Caroline C.
AU - Lieberman, Jay
AU - Stukus, David
AU - Rank, Matthew A.
AU - Ellis, Anne
AU - Abrams, Elissa
AU - Ledford, Dennis
N1 - Publisher Copyright:
© 2023
PY - 2024/3
Y1 - 2024/3
N2 - Background: Guidance addressing atopic dermatitis (AD) management, last issued in 2012 by the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force, requires updating as a result of new treatments and improved guideline and evidence synthesis methodology. Objective: To produce evidence-based guidelines that support patients, clinicians, and other decision-makers in the optimal treatment of AD. Methods: A multidisciplinary guideline panel consisting of patients and caregivers, AD experts (dermatology and allergy/immunology), primary care practitioners (family medicine, pediatrics, internal medicine), and allied health professionals (psychology, pharmacy, nursing) convened, prioritized equity, diversity, and inclusiveness, and implemented management strategies to minimize influence of conflicts of interest. The Evidence in Allergy Group supported guideline development by performing systematic evidence reviews, facilitating guideline processes, and holding focus groups with patient and family partners. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach informed rating the certainty of evidence and strength of recommendations. Evidence-to-decision frameworks, subjected to public comment, translated evidence to recommendations using trustworthy guideline principles. Results: The panel agreed on 25 recommendations to gain and maintain control of AD for patients with mild, moderate, and severe AD. The eAppendix provides practical information and implementation considerations in 1-2 page patient-friendly handouts. Conclusion: These evidence-based recommendations address optimal use of (1) topical treatments (barrier moisturization devices, corticosteroids, calcineurin inhibitors, PDE4 inhibitors [crisaborole], topical JAK inhibitors, occlusive [wet wrap] therapy, adjunctive antimicrobials, application frequency, maintenance therapy), (2) dilute bleach baths, (3) dietary avoidance/elimination, (4) allergen immunotherapy, and (5) systemic treatments (biologics/monoclonal antibodies, small molecule immunosuppressants [cyclosporine, methotrexate, azathioprine, mycophenolate, JAK inhibitors], and systemic corticosteroids) and UV phototherapy (light therapy).
AB - Background: Guidance addressing atopic dermatitis (AD) management, last issued in 2012 by the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force, requires updating as a result of new treatments and improved guideline and evidence synthesis methodology. Objective: To produce evidence-based guidelines that support patients, clinicians, and other decision-makers in the optimal treatment of AD. Methods: A multidisciplinary guideline panel consisting of patients and caregivers, AD experts (dermatology and allergy/immunology), primary care practitioners (family medicine, pediatrics, internal medicine), and allied health professionals (psychology, pharmacy, nursing) convened, prioritized equity, diversity, and inclusiveness, and implemented management strategies to minimize influence of conflicts of interest. The Evidence in Allergy Group supported guideline development by performing systematic evidence reviews, facilitating guideline processes, and holding focus groups with patient and family partners. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach informed rating the certainty of evidence and strength of recommendations. Evidence-to-decision frameworks, subjected to public comment, translated evidence to recommendations using trustworthy guideline principles. Results: The panel agreed on 25 recommendations to gain and maintain control of AD for patients with mild, moderate, and severe AD. The eAppendix provides practical information and implementation considerations in 1-2 page patient-friendly handouts. Conclusion: These evidence-based recommendations address optimal use of (1) topical treatments (barrier moisturization devices, corticosteroids, calcineurin inhibitors, PDE4 inhibitors [crisaborole], topical JAK inhibitors, occlusive [wet wrap] therapy, adjunctive antimicrobials, application frequency, maintenance therapy), (2) dilute bleach baths, (3) dietary avoidance/elimination, (4) allergen immunotherapy, and (5) systemic treatments (biologics/monoclonal antibodies, small molecule immunosuppressants [cyclosporine, methotrexate, azathioprine, mycophenolate, JAK inhibitors], and systemic corticosteroids) and UV phototherapy (light therapy).
UR - http://www.scopus.com/inward/record.url?scp=85185902026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85185902026&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2023.11.009
DO - 10.1016/j.anai.2023.11.009
M3 - Article
AN - SCOPUS:85185902026
SN - 1081-1206
VL - 132
SP - 274
EP - 312
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 3
ER -